Heat shock protein 70 (Hsp70) is an important molecular chaperone that regulates 25 oncoprotein stability and tumorigenesis. However, attempts to develop anti-chaperone 26 drugs targeting molecules such as Hsp70 have been hampered by toxicity issues. Hsp70 27 is regulated by a suite of co-chaperone molecules that bring "clients" to the primary 28 chaperone for efficient folding. Therefore, rather than targeting Hsp70 itself, here we have 29 examined the feasibility of inhibiting the co-chaperone HDJ2, a member of the J domain 30 protein family, as a novel anticancer strategy. We found HDJ2 to be upregulated in a 31 variety of cancers, suggesting a role in malignancy. To confirm this role, we screened the 32 NIH Approved Oncology collection for chemical-genetic interactions with loss of HDJ2 in 33 cancer. 41 compounds showed strong synergy with HDJ2 loss, whereas 18 dramatically 34 lost potency. Several of these hits were validated using a HDJ2 inhibitor (116-9e) in 35 castration-resistant prostate cancer cell (CRPC) and spheroid models. Taken together, 36 these results confirmed that HDJ2 is a hub for anticancer drug resistance and that HDJ2 37 inhibition may be a potent strategy to sensitize cancer cells to current and future 38 therapeutics. 39 40 41 42 104 Materials and Methods 105 Cell culture. The HAP1 Chronic Myelogenous Leukemia cancer cell line and HDJ2 106 Knockout cell line was purchased from Horizon Discovery and were cultured in Iscove's 107 Modified Eagle Medium (Invitrogen) with 10% fetal bovine serum (Gibco), 100 units/ml 108 penicillin, and 100 μg/ml streptomycin at 5% CO2 and 37° C. The LNCaP cancer cell line 109 was purchased from ATCC and were cultured in RPMI-1640 medium (Invitrogen) with 110 10% fetal bovine serum (FBS, Clontech), 100 units/ml penicillin, and 100 μg/ml 111 streptomycin at 5% CO2 and 37° C. 112 6 Drug Screening. Approved Oncology Drug plates consisting of the most current FDA 113 approved anticancer drugs were obtained from National Cancer Institute (NCI). For 114 experiments delineating the synergy between the loss of HDJ2 and approved anticancer 115 drug, HAP1 cells and HAP1 (HDJ2 KO) cells were plated in growth media at 20% 116 confluency 1 day prior to drug treatment. On Day 1 of treatment, cells were treated with 117 DMSO (control), Approved oncology anticancer drugs at 50 µM for 72 hours. Following 118 drug treatments, Cell Titer-Glo reagent was added directly to the wells according to 119 manufacturer's instructions. The luminescence was measured on Bio-Tek Plate reader. 120 Luminescence reading was normalized to and expressed as a relative percentage of the 121 plate averaged DMSO control. The data shown are the mean and SEM of three 122 independent biological replicates. 123 Combination index (CI) calculations. For IC50 calculations, LNCaP cells were seeded 124 in triplicates in 96-well white bottom Nunc plates in growth media at 20% confluency 1 day 125 prior to initiation of drug treatment. On Day 1 of treatment, cells were treated with DMSO 126 (control) and ten folds serial dilution of anti-cancer drugs Cabozantinib, Clofarabine, 127 Vinblastine, Sorafenib, Idarubicin and Omacetaxine mepesuccinate and 116-9e. After 128 72 h, cell viability was measured using Promega Cell Titer-Glo cell viability assay on Bio-129 Tek plate reader. The combination index was calculated using the Chou-Talalay method 130 using CompuSyn software[28]. 131 Spheroid Generation. Single-cell suspensions (5000/well) were plated in one well of 24-132 well plates in a 1:1 mixture of RPMI medium and Matrigel (BD Bioscience CB-40324). 133 Cells in Matrigel are kept cold at all times and under continuous agitation. Warm PBS is 134 added to all empty wells, if any. Plates are incubated at 37 °C with 5% CO2 for 15 min to 135 368 397 18 8. Hageman J, van Waarde MA, Zylicz A, Walerych D, Kampinga HH. The diverse members 398 of the mammalian HSP70 machine show distinct chaperone-like activities. Biochem J.
Introduction 43 44
Hsp70 is a molecular chaperone that plays important roles in protein quality control 45 processes such as protein folding, transport, degradation, regulation and aggregation 46 prevention [1] . Hsp70 levels are elevated in various cancers and overexpression 47 correlates with poor prognosis for survival and response to cancer therapy [2] . The 48 elevated levels of Hsp90 and Hsp70 chaperones in cancer and their role in fostering 49 multiple oncogenic pathways has made these proteins attractive drug targets with 50 numerous anti-chaperone compounds having been developed so far [3] . Problematically, 51
Hsp70 is required for cell survival and protein homeostasis, and thus its inhibition is 52 detrimental to the viability of both normal and cancer cells, with dubious selectivity for 53 tumor cells [4] . 54
Hsp70 performs all its functions in association with a large spectrum of helper 55 proteins known as co-chaperones that include J-proteins, tetratricopeptide repeat (TPR) 56 domain-containing proteins and nucleotide exchange factors (NEFs) which fine-tune 57
Hsp70 specificity and activity in the cell. The J-proteins recruit the protein substrates or 58 clients and interact with such clients at the interface of NBD and SBDb of Hsp70 [5] . This 59 interaction leads to increased Hsp70-mediated ATP turnover and activation of protein 60 folding. J-proteins have a highly conserved 70 amino acid motif containing Histidine, 61
Proline and Aspartic acid amino acid residues known as HPD motif which is essential for 62 stimulating ATPase activity of Hsp70 [6] . In humans, the J-protein family has about 50 63 members which are further divided into three groups based on the localization of J domain 64 within a protein [7, 8] . DNAJA1 (more commonly referred to as HDJ2) associates with 65 unfolded polypeptide chains, preventing their aggregation [7] . Several Hsp70 inhibitors 66 4 have failed in clinical trials due to their toxicity. More recently, alternative strategies have 67 focused on sensitizing cells to anticancer agents by either manipulating post-translational 68 modification of chaperones or their interaction with specific co-chaperones [4, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . 69 HDJ2 (mammalian homologue of yeast Ydj1) is an interesting possible anticancer target 70 as a key mediator of Hsp70 function that appears to regulate specific features of 71 tumorigenesis [13, 20, 21] . A recent study demonstrated that CRPCs expressing ARv7 72 are insensitive to Hsp90 inhibitors but are sensitive to Hsp40 inhibition [22] . In addition, 73
we have shown that targeting specific oncoprotein complexes (ribonucleotide reductase) 74
with a combination of traditional as well as an HDJ2 inhibitor produces highly synergistic 75 effects [13] . We propose that targeting HDJ2 in cancer may offer an attractive alternative 76 to the toxicity induced by full Hsp90/Hsp70 inhibition. 77
Anticancer monotherapies using broadly active cytotoxic or molecularly targeted 78 drugs are limited in their ability to demonstrate a reliable clinical response. This is due to 79 redundant signaling pathways, feedback loops and resistance mechanisms in the cancer 80 cells [23, 24]. Thus, combination anticancer therapies have been used clinically for over 81 50 years to improve the responses achieved by monotherapies alone. Cancer cell line-82 based models for these combination therapies are easy and inexpensive to perform using 83 high-throughput drug screening protocols (HTS) to identify the most effective drug 84 combination [25, 26] . HTS helps to explore the relation between the cell line 85 characteristics and drug specific dose responses [25] . Chemogenomics is one such HTS 86 based approach where large collection of anticancer chemical drugs are screened to 87 identify biological targets. These screening sets often contain small molecules that are 88 well annotated and have defined molecular targets. Such an approach is particularly 89 5 beneficial for cancer research because malignant cells often contain multiple aberrations 90 which require targeted therapy to inactivate cancer driver activities and mitigate 91 deleterious effects of the drugs to normal cells [24, 27] . 92
Here, we performed an unbiased screen of the NIH Approved Oncology Drug set 93 containing 131 anti-cancer drugs in combination with HAP1 cancer cell lines depleted of 94 J-protein HDJ2. We identified 41 compounds showing strong synergy with the loss of 95 HDJ2, and by contrast 18 molecules displaying reduced potency in the knockout cell line. 96
We validated three drugs (cabozantinib, clofarabine and vinblastine) in combination with 97 a unique HDJ2 inhibitor (116-9e) for synergy in the LNCaP cancer cell lines and confirmed 98 omacetaxine mepesuccinate, idarubicin and sorafenib for antagonism (i.e. with reduced 99 potency after HDJ2 inhibition). This study demonstrates the validity of developing Hsp70 100 co-chaperone inhibitors to sensitize cells to current anticancer therapies and suggests 101 that determining HDJ2 status of a tumor may be beneficial in selecting the most 102 appropriate course of treatment. 103 7 solidify the gel before addition of 100 µl of pre-warmed RPMI to each well. Two days after 136 seeding, medium is fully removed and replaced with fresh RPMI containing the indicated 137 drugs. The same procedure is repeated daily on two consecutive days. Twenty-four hours 138 after the last treatments, media is removed and wells are washed with 100 µl of pre-139 warmed PBS. To prepare for downstream assays, spheroids are then released from 140
Matrigel by incubating at 37 °C for 40 min in 100 µl of 10 mg/mL dispase (Sigma). 
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HDJ2 is mutated and overexpressed in a variety of cancers. 158 8 We first investigated the incidence of HDJ2 alterations in cancer using cancer genomics 159 databases. Mutations and copy number changes occur in HDJ2 at a relatively low level 160 (<5% of samples) in the majority of cancer types ( Figure 1) . However, the data shows 161 that HDJ2 is strikingly amplified in neuroendocrine prostate cancer (NEPC) at a frequency 162 of 18.42% ( Figure 1A) . Additionally, HDJ2 is mutated in 11.1% of Non-Small Cell Lung 163 Cancer (NSCLC) cases ( Figure 1A ). Hsp70 and Hsp90 are often overexpressed in tumors 164 Clofarabine is phosphorylated intracellularly to form cytotoxic active 5'-triphosphate 285 metabolite, which inhibits the enzymatic activities of RNR and DNA polymerase, resulting 286 in inhibition of DNA synthesis and repair [54] . In addition, we also identified PARP 287 inhibitors olaparib and niraparib and the topoisomerase inhibitors etoposide, teniposide, 288 valrubicin and dexrazoxane to have increased potency in our screen. 289
While most DDR inhibitors displayed increased potency with HDJ2 depletion, four 290 of them were antagonistic to loss of HDJ2. These include topoisomerase inhibitors and 291 nucleic acid synthesis inhibitors such as trifluridine, irinotecan, epirubicin (4'-epi-isomer 292 of the antibiotic doxorubicin) and idarubicin (4-demethoxy analogue of daunorubicin) [55] . 293
While at first these results seem paradoxical, it is worth noting that inrinotecan is a type I 294 14 topoisomerase inhibitor, whereas Etoposide inhibits the type II class. It may be that Hsp70 295 and HDJ2 play different regulatory roles in the stabilization and activation of these related 296 proteins. It should be noted that both idarubicin and epirubicin trigger TOPII-mediated 297 DNA cleavage. The effects of these molecules may be prevented if HDJ2 alters the 298 function of TOPII. 299
In addition to DDR, HDJ2 is also involved in signal transduction, with previous reports 300 indicating that the yeast homologue of HDJ2 (Ydj1) is critical for supporting the integrity 301 of kinase signaling networks [56] . HDJ2 is mobilized to specific sites within the nucleus in 302 response to inappropriate targeting or folding of specific mutant receptors. HDJ2 303 overexpression ameliorates defective transactivation and trans repression activity of 304 mutant Glucocorticoid receptors [57] . In line with the previous studies, we found that a 305 handful of Receptor Tyrosine kinase inhibitors were synergistic with HDJ2 depletion. 306
These included Vascular endothelial growth factor receptor (VEGFR) inhibitors such as 307 sunitinib, cabozantinib, lenvatinib and pazopanib. Interestingly, randomized phase III 308 clinical trials are being conducted to validate the efficacy of Cabozantinib in heavily 309 pretreated prostate cancer patients [58] . One implication from our study is that HDJ2 310 inhibition might significantly enhance the effect of cabozantinib monotherapy. 311
Strikingly, some of the kinase inhibitors were antagonistic to HDJ2 depletion. These 312 include VEGFR inhibitors such as regorafenib and sorafenib. This disparity can be 313 explained by the different target receptors and mechanisms of action of these drugs. 314
Interestingly, recent studies indicated that these small molecule inhibitors exhibit off-315 target effects. Some of these drugs are misidentified and mischaracterized for their target 316 specific inhibition, which has contributed to the high failure rate of these drugs in treatment 317 of cancer patients [59] . 318
Other than its role in signal transduction, HDJ2 is also important for maintaining the 319 cellular cytoskeleton. Previous studies have suggested that YDJ1 (yeast homolog of 320 HDJ2) is important for the proper assembly of microtubules [60, 61] . Another report 321 showed that HDJ2 depletion causes relocation of N-cadherin and enhanced activity of 322 metalloproteinases. This leads to changes in the actin cytoskeleton indicating that HDJ2 323 is important for prevention of the amoeboid-like transition of tumor cells [62]. These 324 studies indicated the involvement of HDJ2 in maintaining cytoskeletal organization. We 325 found 3 anticancer drugs targeting the cytoskeleton to be synergistic with HDJ2 depletion, 
